ACT Brief: Trial Transparency and Synthetic Controls, Readiness as Leading Risk Indicator, FDA Streamlines Biosimilar Pathway

In today's ACT Brief, we explore the transparency demands of complex trial designs and synthetic controls, how measuring site readiness during training predicts protocol execution, and the FDA's streamlined biosimilar development pathway aimed at reducing drug costs.